Sorrento Starts Patient Dosing In Mid-Stage COVID-19 Trial With Nasal Neutralizing Antibody

Sorrento Therapeutics Inc SRNE has started dosing COVID-19 patients in its Phase 2 efficacy trial. 

  • This study uses a decentralized design where subjects are assessed and treated in their homes.
  • It received a rapid review and clearance from the Medicines and Healthcare products Regulatory Agency (MHRA) in the U.K.
  • Approximately 350 outpatients with COVID-19 who are asymptomatic or have mild symptoms will be enrolled in this large trial evaluating COVIDROPS doses of 10 mg or 20 mg against placebo. 
  • A previously completed safety study conducted in the U.S. at doses up to 60 mg in healthy subjects showed a comparable safety profile to placebo. All reported adverse effects were mild in severity. 
  • COVIDROPS is administered as a simple intranasal instillation into each nostril to recently infected subjects. 
  • The neutralizing antibody drug substance is the same antibody as COVI-AMG, a high potency/low dose IV push injection. 
  • Price Action: SRNE shares are up 7.32% at $8.94 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefsPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!